Evidence map›Paper›PMID 32082376›Full record

ArticleJournal of oncology2019

Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches.

H P Ellis, C E McInerney, D Schrimpf, F Sahm, A Stupnikov, M Wadsley, C Wragg, P White, K M Prise, D G McArt and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

H P Ellis *Brain Tumour Research Centre, University of Bristol, Bristol, UK.
C E McInerney *Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.
D SchrimpfDepartment of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
F SahmDepartment of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
A StupnikovCentre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.
M WadsleyBristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK.
C WraggBristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK.
P WhiteApplied Statistics Group, University of the West of England, Bristol, UK.ORCID https://orcid.org/0000-0002-7503-9896
K M PriseCentre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.
D G McArtCentre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.ORCID https://orcid.org/0000-0001-6426-8776
K M KurianBrain Tumour Research Centre, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0003-0303-3716
Queen's University Belfast · GBHeidelberg University · DENorth Bristol NHS Trust · GBUniversity of Bristol · GBUniversity of the West of England · GB

Funding

Medical Research Council G0701018Medical Research Council G1100578Medical Research Council MR/N004272/1
6 · The paper itself

Abstract

Glioblastoma is the most common primary adult brain tumour, and despite optimal treatment, the median survival is 12-15 months. Patients with matched recurrent glioblastomas were investigated to try to find actionable mutations. Tumours were profiled using a validated DNA-based gene panel. Copy number variations (CNVs) and single nucleotide variants (SNVs) were examined, and potentially pathogenic variants and clinically actionable mutations were identified. The results revealed that glioblastomas were

Identifiers

PMID32082376
PMCPMC7012245
OpenAlexW2998621503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.